Announcements Trials
Browse Landscape

Status

Recruiting 58Active not recruiting 31Completed 28Not yet recruiting 17Terminated 7Enrolling by invitation 2Available 2Withdrawn 1No longer available 1

Sponsor Class

INDUSTRY 2

Study Type

Expanded_access 2

Sponsor

Cancer Type

Gastrointestinal 2Sarcoma 1Lymphoid 1Gynecologic 1Genitourinary 1CNS 1Breast 1

Conditions

Neoplasms 8Carcinoma, Non-Small-Cell Lung 7Pancreatic Neoplasms 6Sarcoma 5Recurrence 4Prostatic Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Ovarian Neoplasms 4Neuroblastoma 4Multiple Myeloma 4Breast Neoplasms 4Melanoma 3Lymphoma, Large B-Cell, Diffuse 3Leukemia, Myeloid, Acute 3Hematologic Neoplasms 3Head and Neck Neoplasms 3Urinary Bladder Neoplasms 2Stomach Neoplasms 2Small Cell Lung Carcinoma 2Primary Myelofibrosis 2Osteosarcoma 2Non-Muscle Invasive Bladder Neoplasms 2Neuroectodermal Tumors, Primitive 2Myelodysplastic Syndromes 2Lymphoma, Non-Hodgkin 2Lymphoma, Follicular 2Lymphoma 2Insulinoma 2Hypoglycemia 2Hyperinsulinism 2

Interventions

Proton Pump Inhibitors 1Hydrocortisone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Available × Carcinoma, Squamous Cell × 1 year × Clear all
NCT06910137 2026-01-08

An Early Access Program Guideline to Provide Access to Retifanlimab (INCMGA00012) Together With Carboplatin and Paclitaxel for Squamous Carcinoma of the Anal Canal (SCAC)

Incyte Corporation

Available
Gastrointestinal

Anus Neoplasms, Carcinoma, Squamous Cell

NCT05974410 2025-10-02

Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients

AVM Biotechnology Inc

Available
BreastCNSGastrointestinalGenitourinaryGynecologicLymphoidSarcoma

Brain Neoplasms, Breast Neoplasms, Carcinoma, Squamous Cell, Glioblastoma, Hodgkin Disease, Lymphoma, Non-Hodgkin, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡